+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07772024

Evaluating Inobrodib with Pomalidomide and Dexamethasone Compared to Standard Therapy for Relapsed or Refractory Multiple Myeloma in a Phase 3 Randomized Study

Led by CellCentric Ltd. · Updated on 2026-08-19

450

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether inobrodib combined with pomalidomide and dexamethasone works better than standard treatments for adults with multiple myeloma that has returned or not improved after previous therapy. This phase 3, randomized, open-label study involves participants who have had one to four prior treatment courses, including therapies targeting CD38 and lenalidomide. The study aims to compare how long participants live without their disease worsening and how many respond to treatment, along with overall survival and quality of life measures. Participants are randomly assigned to one of two groups. One group receives inobrodib orally twice daily for four days followed by three days off each week, along with daily pomalidomide on days 1 to 21 of each 28-day cycle and weekly dexamethasone. The other group receives a standard treatment chosen by the study doctor, which may include combinations of elotuzumab, daratumumab, pomalidomide, carfilzomib, and dexamethasone. Treatments continue until disease progression, unacceptable side effects, or withdrawal. Throughout the study, participants undergo regular assessments including symptom and side effect reviews, vital sign checks, heart tracing tests, blood and urine tests, scans as needed, bone marrow samples, and questionnaires about daily life. Those in the inobrodib group have extra blood samples to measure drug levels. Researchers monitor progression-free survival, response rates, duration of response, minimal residual disease, quality of life scores, and side effects. The study may last up to about 48 months for each participant, with ongoing evaluations during and after treatment.

CONDITIONS

Brief Title

Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

Research Team

C

CCS1477-05 Clinical Operations

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here